You are here

Transcriptional silencing of latent HIV infection - a novel small molecule class

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43AI110186-01A1
Agency Tracking Number: R43AI110186
Amount: $291,941.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIAID
Solicitation Number: PA10-123
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
3550 GENERAL ATOMICS COURT
SAN DIEGO, CA 92121-1122
United States
DUNS: 17703437
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 VENKATA MACHERLA
 (858) 909-5685
 venkat.macherla@sirenasmd.com
Business Contact
 TAMARA MAYER
Phone: (858) 909-5685
Email: tamara.mayer@sirenasmd.com
Research Institution
 Stub
Abstract

DESCRIPTION: Though highly effective in changing the course of the global HIV epidemic, current Antiretroviral Therapy (ART) fails to eradicate the infection completely. This has led to the emergence of drug-resistant mutant strains, the phenomenon of latent disease and a number of adherence and toxicity issues associate with long-term therapy. Novel compounds that inhibit transcription from integrated viral genomes, thereby preventing the production of vira particles from stable viral reservoirs, present avaluable and differentiated therapeutic potential in the treatment of HIV. Tat, a potent transactivator of HIV gene expression essential for the synthesis of full-length transcripts of the integrated viral genome by RNA polymerase II, is a highly soughtafter transcription target for the treatment of HIV. Innovation: Didehydro-cortistati A (dCA), a representative of the cortistatin class of compounds, has demonstrated significant potential as a potent inhibitor of Tat. Preliminary Data: dCA has been

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government